Background. Women with ductal carcinoma in situ (DCIS) are increasingly choosing bilateral mastectomy. We sought to quantify rates of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) for DCIS, and to compare risk factors for CBC and IBTR. Methods. From 1978 to 2011, DCIS patients undergoing BCS with a contralateral breast at risk were identified from a prospectively maintained database. The association of clinicopathologic and treatment factors with CBC and IBTR were evaluated using Kaplan-Meier analysis, multivariable Cox regression, and competing risk regression (CRR). Results. Of 2759 patients identified, 151 developed CBC and 344 developed IBTR. Five-and 10-year Kaplan-Meier CBC rates were 3.2 and 6.4%. Overall, 10-year IBTR rates were 2.5-fold higher than CBC rates, and, without radiation, 4-fold higher. On CRR, 5-and 10-year rates were 2.9 and 5.8% for CBC, and 7.8 and 14.5% for IBTR. CBC risk and invasive CBC risk were not significantly associated with age, family history, presentation, nuclear grade, year of surgery, or radiation. By multivariable Cox regression, endocrine therapy was associated with lower CBC risk (hazard ratio 0.57, p = 0.03). Ten-year risk of subsequent CBC in the subset of patients who developed IBTR was similar to the cohort as a whole (8.1 vs. 6.4%). Conclusions. CBC rates were low across all groups, including those who experienced IBTR. CBC was not associated with factors that increase IBTR risk. While factors associated with IBTR risk are important in decision making regarding management of the index DCIS, they are not an indication for contralateral prophylactic mastectomy.
Furthermore, few studies have examined the risk of CBC in women undergoing breast-conserving surgery (BCS) for DCIS, a group inherently different than those treated with unilateral mastectomy. Similarly, little data on factors predictive of CBC following DCIS have been published.
We sought to quantify the risk of CBC in women with DCIS treated with BCS, and to compare this with the risk of ipsilateral breast tumor recurrence (IBTR) in the same population. Secondarily, we sought to assess if factors known to be associated with IBTR risk were also associated with an increased risk of CBC. Our goal was to provide data to aid in shared decision making regarding the surgical approach to unilateral DCIS for women in whom BCS is feasible.
METHODS
Following Institutional Review Board approval, all patients with a contralateral breast at risk for the subsequent development of breast cancer were identified from a prospectively maintained database of DCIS patients treated with BCS at Memorial Sloan Kettering Cancer Center from 1978 to 2011. Those with a diagnosis of CBC prior to or synchronous with the diagnosis of DCIS, as well as those who underwent contralateral mastectomy, were excluded.
Clinicopathologic factors were collected based on the index DCIS, including age at diagnosis (B49 or C50 years), presentation (radiologic or clinical), family history of breast cancer (one or more first-or second-degree relatives), nuclear grade (low or intermediate/high), treatment time period (B1998 or C1999), and use of adjuvant radiation and endocrine therapy for the index DCIS. Cases of markedly atypical ductal hyperplasia bordering on or focally reaching DCIS were included as lowgrade DCIS.
The primary endpoint was time from definitive surgery for the initial DCIS to diagnosis of CBC, including either DCIS or invasive breast cancer. The Kaplan-Meier method was used to calculate 5-and 10-year CBC estimates for the entire population, and by each clinicopathologic factor for the index DCIS, with differences assessed using the logrank test. Multivariable Cox models were fit to evaluate the relationship between clinicopathologic factors and CBC risk. In a subset analysis, patients who experienced an IBTR following BCS for DCIS were analyzed to describe their risk of CBC after IBTR, with time-to-event defined as the time interval from IBTR to subsequent CBC.
Competing risk analysis was used to evaluate differences in the risk of CBC with that of IBTR. 13 IBTR included ipsilateral recurrence in the breast and axilla, or, in a single case, as metastatic disease in the absence of locoregional recurrence or CBC. The endpoint was defined as the time interval from definitive surgery for the index DCIS to the first event, either CBC or IBTR. CBC and IBTR were considered competing risks because the development of IBTR and its treatment could modify the subsequent probability of CBC, and vice versa. A single patient with subsequent synchronous IBTR and CBC diagnosed on the same day was excluded from the competing risk analysis. Gray's test was used to evaluate the association of each factor with the cumulative incidence of CBC or IBTR. Competing risk multivariable regression was then used to evaluate factors associated with CBC or IBTR in a single model. 14 A separate competing risk analysis examined invasive CBC or IBTR outcomes.
All analyses were performed in SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) and R version 3.1.1 (The R Project for Statistical Computing, Vienna, Austria).
RESULTS
From 1978 to 2011, 2759 DCIS patients with a contralateral breast at risk for the development of breast cancer underwent BCS. Median follow-up was 6.8 years (range 0.01-29.6), and 846 patients had C10 years of follow-up. A total of 151 patients developed CBC and 344 developed IBTR. Of these, 34 patients developed both CBC and IBTR. Of the 151 patients who developed CBC, 107 were invasive and 42 were DCIS; the type of CBC was unknown in 2 cases. Of the 344 IBTRs, 144 were invasive and 192 were DCIS; the type of IBTR was unknown in 8 cases.
Characteristics of the index DCIS for the entire cohort, as well as those with CBC, IBTR, and both CBC and IBTR, are summarized in Table 1 .
Contralateral Breast Cancer (CBC) Risk
The 5-and 10-year cumulative incidence rates of CBC were 3.2 and 6.4%, respectively (Fig. 1a) . On univariate Kaplan-Meier analysis, CBC risk was not significantly associated with the following index DCIS characteristics: age, family history, presentation, nuclear grade, year of surgery, or radiation (Figs. 1b-g ). Those who received endocrine therapy trended toward a lower risk of CBC (10-year rate 3.2 vs. 7.4%, p = 0.07) (Fig. 1h) . On multivariable analysis, the use of endocrine therapy was significantly associated with lower CBC risk, with a rate decreased by almost half (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.35-0.93, p = 0.03) ( Table 2) .
We performed a subset analysis in the 331 patients who developed an IBTR as a first event after their initial DCIS to determine if their risk of subsequent CBC was greater than that of the cohort as a whole. Their CBC risk at 5-and 10-years after IBTR was 3.7 and 8.1%, respectively.
Competing Risk Analysis of CBC Versus Ipsilateral Breast Tumor Recurrence (IBTR)
Competing risk analysis demonstrated 5-and 10-year CBC rates of 2.9 and 5.8%, respectively, compared with 7.8 and 14.5%, respectively, for IBTR (Fig. 2a) . On univariate competing risk analysis, the only factor significantly associated with the risk of CBC was radiologic presentation of the initial DCIS, with a 10-year CBC risk of 6.3%, compared with a 2.3% risk in those whose initial DCIS was diagnosed clinically (p = 0.01) ( Table 3) . Several factors were associated with the risk of IBTR. Of note, the 10-year IBTR risk was 2.5-fold higher than that of CBC for the entire population (Fig. 2a) , and nearly 4-fold higher for the subset not receiving radiation (Table 3) .
Multivariable analysis utilizing competing risk regression (CRR) identified no characteristics of the initial DCIS to be statistically significantly associated with the risk of subsequent CBC, although several factors were associated with the risk of IBTR (Table 3) .
Competing Risk Analysis of Invasive CBC Versus Invasive IBTR
On competing risk analysis, the 10-year invasive CBC rate was 4.1%, and the invasive IBTR rate was 6.1% (Fig. 2b) . Using multivariable CRR to examine initial DCIS characteristics associated with the development of subsequent invasive CBC or IBTR, only the receipt of endocrine therapy trended towards association with a lower Years after breast-conserving surgery for DCIS 
DISCUSSION
Although disease-specific survival for DCIS is excellent and concerns exist regarding its overtreatment, an increasing number of patients are opting for more extensive surgery to treat DCIS. While the use of unilateral mastectomy for DCIS has decreased slightly over the last two decades, the rate of bilateral mastectomy for DCIS has more than doubled. 1, 4 A variety of factors likely influence patients' decisions to choose bilateral mastectomy, including anxiety, confusion regarding the lack of impact of contralateral mastectomy on IBTR risk, overestimation of CBC risk, desire for reconstructive symmetry, and elimination of the need for future surveillance and possibly future adjuvant therapy. [15] [16] [17] [18] Our aim was to better understand the risk of CBC in women with DCIS treated with BCS. In our cohort of 2759 patients with DCIS, we found the rate of CBC was 3.2 and 6.4% at 5 and 10 years, respectively. On competing risk analysis, the 10-year risk of IBTR was 2.5-fold greater than the risk of CBC for the entire cohort, while among the subset of women not receiving radiation for the initial DCIS, the risk of IBTR was nearly 4-fold higher than CBC (19.5 vs. 5.2%).
The low rates of CBC observed in the current data are similar to those in prior studies. The rate of CBC after early-stage breast cancer was 0.6% per year for patients in the Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 1996. 11 In the limited literature reporting specifically on the risk of CBC among women with DCIS, all treated in the 1990s and earlier, 5-and 10-year rates of CBC were 3.1-4.3% and 6.0-6.8%. 11, 19, 20 Results from our cohort, which includes patients with DCIS treated from 1978 to 2011, confirm the low rate of CBC after DCIS for those treated over a span of more than 30 years and in a more contemporary setting than previous reports. Furthermore, our analysis examined the influence of treatment time period and did not demonstrate a significant change in the rate of CBC in more recent years, although rates of IBTR have fallen significantly. 21 Based on studies of patients with invasive breast cancer, we hypothesized that the risk of CBC would be higher in those with a family history of breast cancer and those at younger ages when diagnosed with DCIS. [22] [23] [24] However, we did not find either factor to be significantly associated with the development of subsequent CBC. Innos and HornRoss found a significantly elevated risk of contralateral invasive cancer (incidence rate ratio 1.35, 95% CI 1.11-1.66), but not contralateral DCIS (incidence rate ratio 0.87, 95% CI 0.64-1.18), among those with their initial DCIS diagnosed at age C65 years, compared with age 50-64 years. 20 Similarly, Li et al. found a diagnosis of DCIS at age C60 years (HR 1.3-1.5, p \ 0.05) to be significantly associated with increased risk of subsequent CBC when compared with younger ages. 25 Unlike our analysis, neither of these studies adjusted for the use of endocrine therapy, which is less commonly utilized in older women. [26] [27] [28] In our cohort, after adjustment for multiple factors on multivariable analysis, use of endocrine therapy for the index DCIS was associated with a 43% lower risk of CBC (HR 0.57, p = 0.03). This is consistent with the two randomized studies that examined the use of tamoxifen in women undergoing BCS for DCIS, which found a 32% (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-24 trial) and 56% (UK-ANZ trial) reduction in CBC. 29, 30 On competing risk analysis, the 10-year risk of IBTR was 2.5-fold greater than the risk of CBC (14.5 vs. 5.8%). On multivariable competing risk analysis, none of the characteristics of the index DCIS were significantly associated with subsequent CBC risk. In contrast, the risk of IBTR was significantly higher when the index DCIS was diagnosed at a younger age, presented clinically, of intermediate/high grade, or treated prior to 1999, all of which are consistent with prior literature. 21, 26, [31] [32] [33] [34] [35] [36] Similar to results from the large, prospective, randomized trials demonstrating that radiation and endocrine therapy decrease IBTR by approximately 50 and 30%, respectively, 29, 30, [37] [38] [39] we found that radiation halved the risk of IBTR (HR 0.46, p \ 0.0001) and endocrine therapy reduced it by approximately 40% (HR 0.59, p = 0.004).
Since the primary goal of treating DCIS is to prevent an invasive recurrence, we examined the risk of subsequent invasive CBC and IBTR after DCIS. The 10-year rate was 4.1% for invasive CBC and 6.1% for invasive IBTR. Women who received endocrine therapy had a borderline significantly lower risk of invasive CBC (HR 0.52, p = 0.058), of similar magnitude to that seen in the UK-ANZ trial (HR 0.47, p = 0.03). 29 Consistent with prior findings from our institution and from the NSABP, younger age and not receiving radiation were associated with a higher risk of invasive IBTR. 26, 30 Receiving endocrine therapy was associated with a nonsignificant reduction in risk of invasive IBTR of a magnitude similar to that observed in NSABP B-24 (current series: HR 0.66, p = 0.11; B-24: HR 0.68, p = 0.03). 30 Many patients who experience an IBTR will be treated with an ipsilateral mastectomy. Since undergoing unilateral mastectomy increases the chance that a woman will choose a contralateral prophylactic mastectomy (CPM), 16 we examined the risk of CBC after IBTR. In this subset, the 10-year rate of CBC was low (8.1%) and similar to that of the overall cohort (6.4%), suggesting that women who experience IBTR are not at a significantly higher risk of future CBC that would mandate CPM.
Our study was retrospective in nature and subject to all associated limitations. The use of radiation and endocrine therapy are correlated with tumor and patient risk factors because they were at the discretion of the treating physician and patient, and reflect perceived risk of recurrence. However, our robust, prospectively maintained database, including detailed clinicopathologic data, allowed us to perform multivariable analysis to adjust for these and other factors that could be confounded and affect risk. Furthermore, our patient population represents a large group of women with DCIS eligible for BCS, and includes a more contemporary cohort than previous studies examining the risk of CBC.
It is essential that a woman considering CPM be aware of her risk of CBC, the excellent overall survival for treated DCIS, the lack of survival benefit with CPM, the increased complications associated with bilateral compared with unilateral mastectomy, and the expected aesthetic results. [40] [41] [42] [43] CPM increases the risk of major complications that require a return to the operating room or hospitalization, implant loss, and skin necrosis, as well as minor complications such as seromas, hematomas, cellulitis, and delayed wound healing. 42 Up to 20-30% of patients who have undergone reconstruction report that outcomes such as cosmetic appearance, numbness or tingling, and sexuality were worse than expected. [44] [45] [46] For these reasons, the use of bilateral mastectomy should be carefully considered, with a discussion of appropriate CBC risk estimates, in particular for patients who are eligible for BCS and have a low risk of CBC.
CONCLUSIONS
Rates of CBC were low across all patient groups, irrespective of age, family history, and characteristics of initial DCIS. Factors associated with an increased risk of IBTR were not predictive of greater CBC risk. For a woman undergoing BCS for DCIS, the 10-year IBTR rate is 2.5-fold higher than the CBC rate, and nearly 4-fold higher than the CBC rate for a woman not receiving radiation. In the subset of women who experienced an IBTR, the subsequent CBC risk was still low, and was comparable with that in the larger cohort. Factors associated with higher IBTR risk may be important in decision making regarding management of the index DCIS, but are not an indication for CPM. A discussion of the risks and benefits of various treatment options, including risk estimates of CBC and IBTR for each, should inform women with DCIS who are candidates for breast conservation.
